Cytoskeleton

The Science of Touch: How New Discoveries About PIEZO2 Could Revolutionize Sensory Disorder Treatment

Every gentle tap, every subtle texture we feel is the result of a complex process converting physical force into electrical signals our brain understands. For years, scientists knew the protein PIEZO2 played a crucial role in this process, but the specifics of how it specialized in detecting light touch – while its relative, PIEZO1, responded to broader forces – remained a mystery. Recent research from Scripps Research is now shedding light on this fundamental aspect of human sensation.

Unlocking the Molecular Mechanism of Touch

Published in Nature, the study clarifies how PIEZO2 detects specific types of force. Researchers used minimal fluorescence photon flux (MINFLUX) super-resolution microscopy to observe PIEZO2 in action, tracking its movements with nanometer-scale precision. This allowed them to see how the protein changes shape when force is applied and directly link those changes to its activity.

“Touch is one of our most fundamental senses, yet we didn’t fully understand how it’s processed at the molecular level. We wanted to see how the structure of PIEZO2 shapes what a cell can actually feel,” explains Professor Ardem Patapoutian, co-senior author of the study.

The Role of Tethering and Filamin-B

The research revealed that PIEZO2 is intrinsically stiffer than PIEZO1 and is physically connected to the cell’s internal scaffolding, the actin cytoskeleton, via a protein called filamin-B. This tethering is key. When a cell is poked, this connection helps convey force to PIEZO2, making it more likely to open and transmit a signal. Interestingly, simple membrane stretching didn’t activate PIEZO2 when this tether was intact.

Disrupting this connection in mouse sensory neurons reduced PIEZO2’s sensitivity to indentation, and unexpectedly allowed it to respond to membrane stretch – a force it normally ignores. This suggests that cells can fine-tune their sensitivity to touch by controlling how PIEZO2 is physically integrated within the cell.

Implications for Sensory Disorders and Future Therapies

Mutations in PIEZO2 are known to cause sensory disorders affecting touch and body awareness. Mutations in filamin-B are also linked to skeletal and developmental conditions. Understanding how these proteins interact provides a clearer framework for interpreting these genetic findings and could pave the way for new therapies.

“Our results shift the perspective on how touch begins at the molecular level,” Patapoutian explains. “A protein’s physical connections inside a cell determine what kinds of forces it can sense. That’s a new way of thinking about how we feel the world around us.”

Future Trends in Sensory Research

This research opens several exciting avenues for future exploration:

Personalized Medicine for Sensory Disorders: A deeper understanding of PIEZO2 and filamin-B interactions could lead to personalized treatments for individuals with sensory processing issues, tailored to their specific genetic mutations.
Prosthetic Technology: Mimicking the natural mechanisms of touch sensation could revolutionize prosthetic limbs, providing users with a more realistic and intuitive sense of touch.
Virtual and Augmented Reality: Enhancing haptic feedback in virtual and augmented reality systems by replicating the nuanced force detection of PIEZO2 could create more immersive and realistic experiences.
Understanding Chronic Pain: Dysregulation of PIEZO2 signaling may contribute to chronic pain conditions. Further research could identify new targets for pain management.

The discovery that tethering plays such a critical role in PIEZO2 function is a significant step forward. It suggests that manipulating these connections could be a viable therapeutic strategy for restoring or enhancing touch sensation.

FAQ

Q: What is PIEZO2?
A: PIEZO2 is a protein that acts as a key sensor for touch, converting physical force into electrical signals the brain can interpret.

Q: What is filamin-B?
A: Filamin-B is a protein that connects PIEZO2 to the cell’s internal scaffolding, helping it respond to force.

Q: How could this research help people with sensory disorders?
A: By understanding how PIEZO2 and filamin-B interact, scientists can develop new therapies to restore or enhance touch sensation in individuals with sensory processing issues.

Q: What is MINFLUX microscopy?
A: MINFLUX is a super-resolution microscopy technique that allows scientists to track the movements of proteins in cells with nanometer-scale precision.

Did you know? The Nobel Prize in Physiology or Medicine was awarded in 2021 to Ardem Patapoutian for his discovery of PIEZO1 and PIEZO2.

Want to learn more about the fascinating world of sensory biology? Explore our other articles on neuroscience and the nervous system.

Recent Alliance Targets Malaria’s Achilles’ Heel: The Parasite’s Skeleton

A groundbreaking research collaboration between the Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc. Promises a fresh approach to combating malaria. Supported by the Gates Foundation, the partnership focuses on disrupting the Plasmodium parasite’s cytoskeleton – a strategy that could unlock a new generation of antimalarial drugs.

The Growing Threat of Drug Resistance

Malaria continues to be a global health crisis, with over 280 million cases and more than 600,000 deaths reported annually. The disease disproportionately impacts children and vulnerable populations in low- and middle-income countries. A major challenge is the increasing resistance of P. Falciparum, the deadliest malaria parasite, to existing treatments. This necessitates the urgent development of medicines with entirely new mechanisms of action.

Targeting the Cytoskeleton: A Novel Approach

Traditionally, antimalarial drug development has focused on metabolic pathways within the parasite. This new collaboration shifts the focus to the parasite’s cytoskeleton – the internal scaffolding that provides structure and enables movement. By disrupting this system, researchers aim to cripple the parasite’s ability to infect and replicate.

“We need to stay ahead of resistance by identifying and advancing compounds with entirely new mechanisms,” explains Case McNamara, senior director of infectious disease at Calibr-Skaggs. “Our collaboration with Kainomyx is designed to do just that: by targeting the parasite’s cytoskeleton, we open up a new front in the battle against this disease.”

Combining Expertise for Accelerated Discovery

The synergy between Calibr-Skaggs and Kainomyx is central to this initiative. Calibr-Skaggs brings its established drug discovery platform and a track record of advancing over a dozen drug candidates into clinical trials. Kainomyx contributes specialized expertise in cytoskeletal proteins, including their identification, purification, and structural analysis.

Kainomyx co-founder James Spudich, who as well co-founded Cytokinetics and MyoKardia, emphasizes the company’s commitment to translating fundamental biological insights into therapies. “Working with Calibr-Skaggs and with support from the Gates Foundation, we have an unprecedented opportunity to bring new hope to millions at risk of malaria,” he stated.

A Collaborative Pipeline

The collaboration will see Kainomyx providing key materials and conducting structural studies, although Calibr-Skaggs will lead medicinal chemistry efforts and high-throughput screening. Both organizations will jointly advance promising compounds through the drug discovery pipeline, with a commitment to open publication and global access.

“Our mission at Kainomyx is to harness the power of cytoskeletal science to address urgent global health challenges,” Spudich added.

Calibr-Skaggs’ Nonprofit Model and Commitment

Calibr-Skaggs’ unique nonprofit model allows it to prioritize global health needs over profit, fostering a collaborative environment for innovation. “Our mission is to translate scientific breakthroughs into real-world solutions for those most in need. Collaborations like this are essential to succeed in the global effort to eradicate malaria,” says Anil Gupta, director of medicinal chemistry at Calibr-Skaggs.

Frequently Asked Questions

What is the cytoskeleton? The cytoskeleton is a network of protein filaments within cells that provides structural support and enables movement.

Why is targeting the cytoskeleton a novel approach? Most current antimalarial drugs target the parasite’s metabolic processes. Targeting the cytoskeleton represents a new mechanism of action, potentially overcoming drug resistance.

What role does the Gates Foundation play? The Gates Foundation provides financial support for the research collaboration, recognizing the urgent need for new antimalarial therapies.

Will these drugs be accessible globally? Both organizations have committed to open publication and global access to any drugs developed through this collaboration.

What is Calibr-Skaggs’ track record? Calibr-Skaggs has advanced over a dozen drug candidates into clinical trials, including promising antimalarial agents.

Understanding PIEZO2 mutations and sensory disorders